Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance

Circulation

Volumn 127, Issue 21, 2013, Pages 2078-2087

  Matsuura, Hirohide ^a   Ichiki, Toshihiro ^a   Inoue, Eriko ^a   Nomura, Masatoshi ^a   Miyazaki, Ryohei ^a   Hashimoto, Toru ^a   Ikeda, Jiro ^a   Takayanagi, Ryoichi ^a   Fong, Guo Hua ^b   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Adipocytes; Cell hypoxia; Obesity; Prolyl hydroxylase domain protein

Indexed keywords

ADIPONECTIN; CRE RECOMBINASE; GLUCOSE; GLYCOLYTIC ENZYME; HYPOXIA INDUCIBLE FACTOR; INSULIN; LACTIC ACID; LIPID; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN PROTEIN 2; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; BODY WEIGHT; BROWN ADIPOSE TISSUE; CELL INFILTRATION; CELL SIZE; CONTROLLED STUDY; DIETARY INTAKE; EPIDIDYMIS FAT; GENE DELETION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE INDEX; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LIPID ANALYSIS; LIPID DIET; MACROPHAGE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RATING SCALE; RECEPTOR UPREGULATION; SUPERNATANT; TRANSGENIC ANIMAL; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

ADIPOCYTES; CELL HYPOXIA; OBESITY; PROLYL HYDROXYLASE DOMAIN PROTEIN;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; CELLS, CULTURED; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; LIPID METABOLISM; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; OBESITY; OXYGEN CONSUMPTION; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 84878313576     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001742     Document Type: Article

References (40)

1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-867.
3. Martínez JA. Mitochondrial oxidative stress and inflammation: an slalom to obesity and insulin resistance. J Physiol Biochem. 2006; 62: 303-306.
4. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457-461.
5. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009; 15: 914-920.
6. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006; 5: 919-931.
7. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121-2134.
8. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370: 1706-1713.
9. Shukla V, Singh SN, Vats P, Singh VK, Singh SB, Banerjee PK. Ghrelin and leptin levels of sojourners and acclimatized lowlanders at high altitude. Nutr Neurosci. 2005; 8: 161-165.
10. Allahdadi KJ, Walker BR, Kanagy NL. Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension. 2005; 45: 705-709.
11. Simler N, Grosfeld A, Peinnequin A, Guerre-Millo M, Bigard AX. Leptin receptor-deficient obese Zucker rats reduce their food intake in response to hypobaric hypoxia. Am J Physiol Endocrinol Metab. 2006; 290: E591-E597.
12. Quintero P, Milagro FI, Campión J, Martínez JA. Impact of oxygen availability on body weight management. Med Hypotheses. 2010; 74: 901-907.
13. Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell. 2002; 2: 331-341.
14. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30: 393-402.
15. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994; 269: 23757-23763.
16. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996; 271: 32529-32537.
17. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006; 3: 177-185.
18. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006; 3: 187-197.
19. Fraisl P, Aragonés J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov. 2009; 8: 139-152.
20. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003; 22: 4082-4090.
21. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006; 26: 8336-8346.
22. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H, Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes. 2007; 56: 1517-1526.
23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808.
24. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821-1830.
25. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007; 21: 1037-1049.
26. Westerterp KR, Kayser B, Wouters L, Le Trong JL, Richalet JP. Energy balance at high altitude of 6,542 m. J Appl Physiol. 1994; 77: 862-866.
27. Westerterp-Plantenga MS, Westerterp KR, Rubbens M, Verwegen CR, Richelet J P, Gardette B. Appetite at "high altitude" [Operation Everest III (Comex-'97)]: a simulated ascent of Mount Everest. J Appl Physiol. 1999; 87: 391-399.
28. Reynolds RD, Lickteig JA, Deuster PA, Howard MP, Conway JM, Pietersma A, de Stoppelaar J, Deurenberg P. Energy metabolism increases and regional body fat decreases while regional muscle mass is spared in humans climbing Mt. Everest. J Nutr. 1999; 129: 1307-1314.
29. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4: 891-899.
30. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010; 140: 280-293.
31. Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH, Schaan BD. GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol. 2012; 11: 100.
32. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond). 2009; 33: 54-66.
33. Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J. Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab. 2009; 296: E333-E342.
34. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56: 901-911.
35. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008; 100: 227-235.
36. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, Wang ZV, Landskroner-Eiger S, Dineen S, Magalang UJ, Brekken RA, Scherer PE. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol. 2009; 29: 4467-4483.
37. Shimba S, Wada T, Hara S, Tezuka M. EPAS1 promotes adipose differentiation in 3T3-L1 cells. J Biol Chem. 2004; 279: 40946-40953.
38. Zhang X, Lam KS, Ye H, Chung SK, Zhou M, Wang Y, Xu A. Adipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in mice. J Biol Chem. 2010; 285: 32869-32877.
39. Zhang N, Fu Z, Linke S, Chicher J, Gorman JJ, Visk D, Haddad GG, Poellinger L, Peet DJ, Powell F, Johnson RS. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab. 2010; 11: 364-378.
40. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7: 489-503.